Latest news with #Chemicals
Yahoo
4 days ago
- Business
- Yahoo
BRAIN Biotech Second Quarter 2025 Earnings: €0.14 loss per share (vs €0.088 loss in 2Q 2024)
Revenue: €12.5m (down 14% from 2Q 2024). Net loss: €3.06m (loss widened by 60% from 2Q 2024). €0.14 loss per share (further deteriorated from €0.088 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Performance of the German Chemicals industry. The company's share price is broadly unchanged from a week ago. You still need to take note of risks, for example - BRAIN Biotech has 1 warning sign we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Egypt Today
6 days ago
- Business
- Egypt Today
Egypt & U.S. Form Joint Venture to Boost Global Pharmaceutical Exports
CAIRO - 28 May 2025: The Holding Company for Pharmaceuticals, Chemicals, and Medical Supplies has entered into a strategic joint venture with American pharmaceutical firm Dawah Pharma. This partnership marks a significant step in Egypt's push to expand its pharmaceutical footprint globally, with plans to manufacture and export a broad range of pharmaceutical products and dietary supplements to international markets. Minister of Public Business Sector Mohamed Shimi announced that the new venture will produce a diverse portfolio of products, including ampoules, sterile injections, ophthalmic solutions, over-the-counter (OTC) medications, and dietary supplements. The joint venture structure grants the Egyptian side a 40 percent share, while Dawah Pharma holds a 60% majority stake. The newly formed company will focus primarily on exporting its products and opening new channels in global markets. In a milestone move, the partnership's first phase will see the manufacture and export of six specific dietary supplements to the United States—marking the first time in the Holding Company's history to achieve such a feat after meeting rigorous international standards and requirements. The agreement also leverages advanced pharmaceutical manufacturing technologies, including the production of syrups, tablets, ampoules, pre-filled syringes, and transdermal patches. These innovations are expected to significantly accelerate product deployment and support long-term growth for the Holding Company and its subsidiaries. Shimi stressed that the new company will strictly follow international regulatory standards, particularly those enforced by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adhering to these benchmarks will boost the global competitiveness of Egyptian pharmaceuticals—not only in the high-demand markets of Europe and North America but also in emerging markets across Africa and Asia.
Yahoo
23-05-2025
- Business
- Yahoo
Flotek Industries' (NYSE:FTK) Returns On Capital Are Heading Higher
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So when we looked at Flotek Industries (NYSE:FTK) and its trend of ROCE, we really liked what we saw. We've discovered 1 warning sign about Flotek Industries. View them for free. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Flotek Industries: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.12 = US$16m ÷ (US$170m - US$44m) (Based on the trailing twelve months to March 2025). So, Flotek Industries has an ROCE of 12%. In absolute terms, that's a satisfactory return, but compared to the Chemicals industry average of 8.6% it's much better. Check out our latest analysis for Flotek Industries In the above chart we have measured Flotek Industries' prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Flotek Industries . We're delighted to see that Flotek Industries is reaping rewards from its investments and has now broken into profitability. The company was generating losses five years ago, but has managed to turn it around and as we saw earlier is now earning 12%, which is always encouraging. Interestingly, the capital employed by the business has remained relatively flat, so these higher returns are either from prior investments paying off or increased efficiencies. That being said, while an increase in efficiency is no doubt appealing, it'd be helpful to know if the company does have any investment plans going forward. After all, a company can only become a long term multi-bagger if it continually reinvests in itself at high rates of return. For the record though, there was a noticeable increase in the company's current liabilities over the period, so we would attribute some of the ROCE growth to that. Essentially the business now has suppliers or short-term creditors funding about 26% of its operations, which isn't ideal. Keep an eye out for future increases because when the ratio of current liabilities to total assets gets particularly high, this can introduce some new risks for the business. As discussed above, Flotek Industries appears to be getting more proficient at generating returns since capital employed has remained flat but earnings (before interest and tax) are up. And a remarkable 156% total return over the last five years tells us that investors are expecting more good things to come in the future. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence. Flotek Industries does have some risks though, and we've spotted 1 warning sign for Flotek Industries that you might be interested in. If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
17-05-2025
- Business
- Yahoo
H&R GmbH KGaA First Quarter 2025 Earnings: EPS: €0.05 (vs €0.04 in 1Q 2024)
Revenue: €357.0m (up 3.9% from 1Q 2024). Net income: €1.89m (up 29% from 1Q 2024). Profit margin: 0.5% (up from 0.4% in 1Q 2024). The increase in margin was driven by higher revenue. EPS: €0.05 (up from €0.04 in 1Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to stay flat during the next 2 years compared to a 3.6% growth forecast for the Chemicals industry in Germany. Performance of the German Chemicals industry. The company's shares are up 26% from a week ago. Before you take the next step you should know about the 2 warning signs for H&R GmbH KGaA that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
10-05-2025
- Business
- Yahoo
Is Akzo Nobel N.V.'s (AMS:AKZA) 11% ROE Better Than Average?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to examine Akzo Nobel N.V. (AMS:AKZA), by way of a worked example. Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits. We've discovered 2 warning signs about Akzo Nobel. View them for free. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Akzo Nobel is: 11% = €518m ÷ €4.9b (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each €1 of shareholders' capital it has, the company made €0.11 in profit. See our latest analysis for Akzo Nobel Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. You can see in the graphic below that Akzo Nobel has an ROE that is fairly close to the average for the Chemicals industry (10%). That's neither particularly good, nor bad. While at least the ROE is not lower than the industry, its still worth checking what role the company's debt plays as high debt levels relative to equity may also make the ROE appear high. If so, this increases its exposure to financial risk. Our risks dashboardshould have the 2 risks we have identified for Akzo Nobel. Most companies need money -- from somewhere -- to grow their profits. That cash can come from issuing shares, retained earnings, or debt. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same. Akzo Nobel does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.21. The combination of a rather low ROE and significant use of debt is not particularly appealing. Debt increases risk and reduces options for the company in the future, so you generally want to see some good returns from using it. Return on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. In our books, the highest quality companies have high return on equity, despite low debt. All else being equal, a higher ROE is better. But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. Profit growth rates, versus the expectations reflected in the price of the stock, are a particularly important to consider. So you might want to take a peek at this data-rich interactive graph of forecasts for the company. If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
